Moderna Says COVID Vaccine Has Fewer Breakthrough Cases Than Pfizer, but Higher Myocarditis Rates in Young Men

  • Moderna defended the use of its Covid vaccine, saying the protection it offers against severe disease, hospitalization and death outweighs the risk of myocarditis.
  • Reported cases of the rare heart inflammation in men under 30 are relatively higher after Moderna’s vaccine compared with Pfizer’s, said Chief Medical Officer Dr. Paul Burton.
  • However, he also touted data from the CDC that showed the rates of mild or severe disease from Covid were lower in Moderna recipients.

TO HOME PAGE